Table 3.
Menstrual distress before and after injection treatment and during follow-up cycles
| Cox duration* | Cox intensity* | MMDQ* | Daily activity restriction | Increased hours in bed |
||
|---|---|---|---|---|---|---|
| Study period | Mean | Mean | Mean | Per cent | Mean | SD |
| Baseline cycle 1 | ||||||
| Group A (control for vitamin K) | 1.42 | 1.19 | 1.20 | 96.30 | 6.52 | 3.95 |
| Group B (control for point location) | 1.40 | 1.18 | 1.38 | 100.00 | 6.67 | 4.26 |
| Group C (standard†) | 1.29 | 1.18 | 1.34 | 100.00 | 7.58 | 5.38 |
| Treatment cycle 2 | ||||||
| Group A (control for vitamin K) | 0.84‡ | 0.68‡ | 0.69 | 59.26 | 3.60 | 1.35 |
| Group B (control for point location) | 0.93‡ | 0.68‡ | 0.82 | 74.07 | 5.40 | 2.80 |
| Group C (standard†) | 0.83‡ | 0.69‡ | 0.69§ | 61.54 | 4.57 | 1.81 |
| Cycle 3 | ||||||
| Group A (control for vitamin K) | 0.85 | 0.66 | n/a | 65.38 | 4.33 | 1.30 |
| Group B (control for point location) | 0.93 | 0.76 | n/a | 62.96 | 5.00 | 1.85 |
| Group C (standard†) | 0.73 | 0.57 | n/a | 50.00 | 5.13 | 2.47 |
| Cycle 4 | ||||||
| Group A (control for vitamin K) | 0.90 | 0.65 | n/a | 42.31 | 7.50 | 5.73 |
| Group B (control for point location) | 0.82 | 0.67 | n/a | 55.56 | 5.00 | 1.61 |
| Group C (standard†) | 0.76 | 0.64 | n/a | 46.15 | 5.11 | 1.76 |
| Cycle 5 | ||||||
| Group A (control for vitamin K) | 0.77 | 0.52 | n/a | 42.31 | 7.67 | 5.99 |
| Group B (control for point location) | 0.78 | 0.66 | n/a | 55.56 | 5.11 | 1.76 |
| Group C (standard†) | 0.76 | 0.57 | n/a | 57.69 | 3.60 | 0.52 |
| Cycle 6 | ||||||
| Group A (control for vitamin K) | 0.84 | 0.66 | n/a | 61.54 | 8.14 | 3.18 |
| Group B (control for point location) | 0.93 | 0.77 | n/a | 66.67 | 5.45 | 1.81 |
| Group C (standard†) | 0.87 | 0.63 | n/a | 57.69 | 4.91 | 1.38 |
| Cycle 7 | ||||||
| Group A (control for vitamin K) | 0.79¶ | 0.60¶ | n/a | 57.69 | 4.89 | 2.03 |
| Group B (control for point location) | 0.98¶ | 0.78¶ | n/a | 59.26 | 5.25 | 1.82 |
| Group C (standard†) | 0.77¶ | 0.61¶ | n/a | 50.00 | 5.50 | 2.39 |
*Although all three groups experienced reduction in menstrual distress on the Cox and MMDQ scales between baseline and cycle 2 and between baseline and cycle 7, the only significant difference in group means was on the MMDQ scale between baseline and cycle 2.
†Standard treatment at the Menstrual Disorders Centre, Obstetrics and Gynecology Hospital, Shanghai.
‡Significant difference (p<0.001) between baseline cycle and treatment cycle within group paired comparisons.
§Significant difference (p<0.001) between groups A and C and between groups B and C on menstrual distress.
¶Significant difference (p<0.001) between baseline cycle and last follow-up cycle within group paired comparisons.
MMDQ, Moos Menstrual Distress Questionnaire; n/a, not applicable.